Astin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astin

What is Astin?

Astin is a medication that belongs to a class of drugs known as statins, or HMG-CoA reductase inhibitors. It is primarily used to manage cholesterol levels in the blood. By addressing lipid imbalances, it plays a role in the long-term management of cardiovascular health.

Mechanism of Action

The medication works by inhibiting a specific enzyme in the liver responsible for the production of cholesterol. By reducing the internal synthesis of cholesterol, the body is encouraged to clear existing low-density lipoprotein (LDL), often referred to as "bad" cholesterol, from the bloodstream. Additionally, the medication can help slightly increase high-density lipoprotein (HDL), known as "good" cholesterol, and reduce triglycerides.

Therapeutic Purpose

Astin is utilized for individuals who require assistance in reaching target cholesterol levels that cannot be achieved through diet and exercise alone. Its primary functions include:

  • Lowering LDL Cholesterol: Reducing the amount of fatty deposits that can accumulate in the arteries.
  • Managing Triglycerides: Decreasing specific fats in the blood that contribute to overall lipid profiles.
  • Supporting Vascular Health: Helping to maintain clearer pathways for blood flow over time.

Clinical Application

This medication is typically integrated into a broader management plan that includes a heart-healthy diet, regular physical activity, and weight management. It is intended for long-term use to help manage the risks associated with high cholesterol, such as the gradual narrowing of the arteries.

Regulatory References

  1. NIH: National Library of Medicine

What side effects are possible with Astin?

Possible Side Effects and Safety Information

The safety profile of Astin (Atorvastatin) is formally classified by regulatory authorities based on observed adverse reactions in clinical use. These effects are grouped by frequency and the body system affected, providing a structured overview of potential risks.


Frequency-Classified Adverse Reactions

The official Summary of Product Characteristics (SmPC) and FDA labeling categorize adverse reactions by their observed frequency:

  • Common (occurring in 1 to 10 out of every 100 patients) reactions include nasopharyngitis, headache, myalgia (muscle pain), arthralgia (joint pain), and gastrointestinal effects like diarrhea or nausea.
  • Rare effects (less than 1 in 1,000 patients) include severe reactions like Rhabdomyolysis (severe muscle breakdown), myopathy, peripheral neuropathy, and angioedema.
  • Very Rare effects (less than 1 in 10,000 patients) documented include hepatic failure (liver failure) and anaphylaxis.

Serious Adverse Reactions and Safety Constraints

The most serious safety concerns explicitly documented in official labeling relate primarily to skeletal muscle toxicity. Rhabdomyolysis and myopathy are recognized risks, and advanced age (65 years and older) is listed as a predisposing factor for these conditions.

Use of Astin is Contraindicated (strictly forbidden) in patients with active liver disease or unexplained persistent elevations of liver enzymes. Furthermore, the medicine is Contraindicated during pregnancy and lactation, as stated in official regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Astin (Atorvastatin) overdose does not identify a unique acute syndrome but focuses on managing high-exposure effects, primarily severe muscular and hepatic toxicity. Documented manifestations that signal a need for medical attention include unexplained muscle pain, tenderness, or weakness (myopathy) and signs of liver distress, such as jaundice or elevated laboratory markers like Creatine Kinase and serum transaminases.

Overdose has the potential for severe, documented outcomes, including rhabdomyolysis (severe muscle breakdown), acute kidney injury, and rare instances of hepatic failure. The risk of these serious complications is officially noted as being higher in older adults and those with pre-existing kidney or thyroid problems.

Regulatory documents confirm that no specific antidote is known, and standard procedures like hemodialysis are not expected to be effective due to the substance's properties. Management is mandated as being symptomatic and supportive.

Immediate medical assistance is required if an individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Urgent help must also be sought for the emergence of symptoms strongly linked to severe muscle toxicity, such as unexplained muscle pain, tenderness, or weakness combined with fever or dark urine.

Therapeutic Uses of Astin

What Astin Treats: Main Uses and Benefits

Astin is commonly used to help with managing abnormal blood fat levels, a type of symptoms related to systemic imbalance, and contributes to easing the risk of serious health issues. The medication plays a role in managing the presence of high cholesterol, specifically addressing conditions like primary hypercholesterolemia, mixed dyslipidemia, and inherited forms such as familial hypercholesterolemia.

This supportive approach is considered relevant as a long-term supportive approach relevant in contexts involving heightened systemic burden, and is relevant across clinical settings involving high-risk profiles. The clinical benefit supports patients by easing distress associated with these long-term systemic imbalances. For example, Astin may be part of symptomatic management for specialized populations, including pediatric patients aged 10 and older with inherited high cholesterol.


Quick Facts on Therapeutic Use

Property Description
Primary Use Applied across domains where additional symptomatic support is needed
Symptom Focus Helps address symptom clusters that may become intense or disruptive (systemic imbalance)
Main Benefit Offers symptomatic relief that helps patients cope more steadily with symptom fluctuations
Context Relevant in conditions characterized by periods of heightened symptoms (high risk, chronic dyslipidemia)

Regulatory References

  1. NIH MedlinePlus overview of Atorvastatin uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Astin?

Official regulatory documents define strict population eligibility criteria for Astin (Atorvastatin).

Absolute Contraindications (Must Not Use) Astin is contraindicated and must not be used by patients with active liver disease, including those with unexplained, persistent elevations in liver enzymes, or a known hypersensitivity to the drug or any of its components. Furthermore, Astin is contraindicated during pregnancy and in women who are breastfeeding or lactating. Females of reproductive potential must use effective contraception during treatment.

Age-Related Eligibility Use is generally established for adult patients. For pediatric patients, use is not established and contraindicated in those younger than 10 years old. For children aged 10 and above, eligibility is restricted to those with specific diagnoses, such as Familial Hypercholesterolemia.

Conditional Use and Risk Factors Populations with certain pre-existing conditions are classified as having risk factors. This includes individuals with uncontrolled hypothyroidism and patients of advanced age (ge 65 years). These groups require specific consideration due to an increased risk of potential muscle effects. While renal impairment is listed as a risk factor, regulatory labeling specifies that dose adjustment is typically not required based on renal function alone.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Astin (Atorvastatin) is defined by its role as a substrate for the CYP3A4 enzyme and specific drug transporters, leading to significant pharmacokinetic and pharmacodynamic interactions documented in regulatory labeling.

Official Interaction Statements

The combination of Atorvastatin with specific hepatitis C antivirals, such as Glecaprevir plus Pibrentasvir, and the immunosuppressant Ciclosporin is formally documented as contraindicated due to the risk of greatly increased systemic exposure. The co-administration of Atorvastatin with strong CYP3 A4 inhibitors, including Itraconazole and Clarithromycin, also results in a marked increase in its plasma concentration.

Interaction Type Interacting Agent Examples Effect on Astin Exposure
Metabolic/Transporter Inhibition Ciclosporin, Clarithromycin, Itraconazole Increased (via CYP3 A4/Transporters)
Metabolic Induction Rifampin, St. John's Wort Decreased (via CYP3 A4)

Pharmacodynamic interactions exist with Fibric Acid Derivatives (e.g., Gemfibrozil) and Lipid-Modifying Doses of Niacin (ge 1 g/day), resulting in an additive risk of myopathy. To prevent a significant reduction in plasma levels, Rifampin must be co-administered simultaneously with Atorvastatin. Furthermore, Atorvastatin itself may increase the plasma concentration of certain co-administered drugs, including Digoxin and specific Oral Contraceptives. These documented restrictions are amplified in individuals with Hepatic Impairment, where Atorvastatin exposure is already markedly increased.

Mechanism of Action

Astin exerts its pharmacodynamic effects primarily by targeting the enzyme HMG-CoA reductase in the liver. Acting as a competitive inhibitor, the drug blocks the rate-limiting step of the mevalonate pathway, directly suppressing the liver's internal production of cholesterol. The resulting cellular cholesterol deficit triggers a critical compensatory feedback loop: the upregulation of LDL receptors on the surface of liver cells. This increased receptor density significantly enhances the liver's capacity to extract LDL cholesterol (LDL-C) and other atherogenic lipoproteins from the bloodstream, facilitating a reduction in their plasma concentration. Secondary, non-lipid actions (pleiotropic effects) include the modulation of systemic and local vascular inflammation and the improvement of endothelial function. This influence helps modulate structural elements of the vessel walls, constituting a secondary physiological consequence independent of the drug's primary lipid-modifying mechanism.

Dosage and Administration Information

How to Use Astin: Administration Guidelines

Astin (Atorvastatin) is designed exclusively for oral administration and is typically supplied as film-coated tablets in strengths ranging from 10 mg to 80 mg. The tablets are taken once daily and may be consumed with or without food and at any time of the day. This simple frequency and contextual instruction establish a highly flexible regimen for daily intake.

Dosing and Schedule

For most adult patients, the standard starting dose is 10 mg or 20 mg once daily. Doses are not adjusted frequently; dosage changes, if necessary, should only occur after a minimum interval of four weeks to allow for assessment of response before titration. The maximum approved dose for adults is 80 mg once daily.

Instruction Detail
Administration Route Oral administration only.
Frequency Once daily (qDay).
Timing in Relation to Food Tablets may be taken with or without food.
Missed-Dose Rule Skip the missed dose and resume with the next regularly scheduled dose.

Population-Specific Use

Specific dosing rules apply to certain populations. For instance, pediatric patients aged 10 to 17 years being treated for heterozygous familial hypercholesterolemia have an initial dose of 10 mg once daily, with a maximum dose of 20 mg once daily. Importantly, for patients with renal impairment, no dose adjustment is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Astin (Atorvastatin)

Evidence for Use in Lowering Elevated Blood Lipids (Dyslipidemia)

Research has focused on how the levels of various fats circulating in the blood were tracked and measured in studies. Studies conducted over short-to-intermediate time intervals (typically 8 weeks to 1 year) measured outcomes related to systemic or functional imbalance by tracking percentage changes in markers like LDL-C, Total Cholesterol, and Triglycerides. Findings describe patterns observed in the studies, often indicating dose-dependent relationships between the biomarker changes and the amount of active ingredient used. The evidence contributes to understanding how biomarkers evolved in the observed populations by providing insight into short-term changes in lipid levels.

Evidence for Use in Primary Prevention of Cardiovascular Events

This section will outline the structure of the large, long-term randomized controlled trials (RCTs) that studied Astin in adults with cardiovascular risk factors (like hypertension or diabetes) but no established heart disease, where the main objective was tracking the occurrence of first heart attacks and strokes. Large, international RCTs, such as the ASCOT-LLA trial, were conducted to track the occurrence of a first non-fatal heart attack or stroke in adults aged 40 to 79 who had multiple risk factors but no prior history of heart disease. Research describes patterns in the occurrence of these clinical events observed over several years in the groups studied. However, data for initiating this type of therapy in adults aged 76 and older for primary prevention purposes is insufficient or limited in current studies. The evidence suggests findings describe group patterns observed in highly selected trial populations, and research does not determine whether an individual will respond similarly.

What is Still Uncertain About Astin's Evidence

Evidence highlights what is known and what is still uncertain across the research landscape. Data are still emerging regarding the generalizability of trial results to patients with complex multiple chronic health conditions, as these individuals were often excluded from the original RCTs. Furthermore, research has described patterns of change in lipids over the short-term, but the follow-up durations were limited for many studies, meaning that long-term effects are not well characterized. Comparative evidence is lacking for certain statin doses against other therapies in specific high-risk subgroups.

Key Studies & References

  1. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension

Frequently Asked Questions (FAQ)

Common questions about Astin (FAQ)


Q: How quickly can a person expect Astin to start working?

Studies indicate that the therapeutic effect of Astin on blood lipid levels is typically noticeable within two weeks of starting treatment. The maximum response, or full lipid-lowering effect, is usually achieved within four weeks. Monitoring of lipid levels, as described in regulatory information, is typically scheduled around four weeks after treatment initiation.


Q: Is Astin generally considered a long-term or short-term treatment?

Astin is generally intended for chronic, or long-term, therapy. Official studies show that the beneficial effect on lipid levels is maintained over extended periods of consistent use. The duration of treatment is established by a healthcare professional based on individual factors.


Q: Can Astin be taken with other common prescription drugs?

Astin has documented interactions with a number of other prescription drugs. Some medications, such as certain antivirals, are strictly contraindicated for use with Astin. The official product information notes that using Astin with many other medicines may lead to altered exposure and increased risk, which requires careful management by a healthcare professional.


Q: Is there a food or drink that should be avoided while taking Astin?

Yes, the official patient information advises caution regarding grapefruit juice. Consuming large quantities of grapefruit or grapefruit juice can slow down the metabolism of the drug, which may increase its concentration in the bloodstream. This caution is based on documented pharmacokinetic interactions described in the regulatory information.


Q: Is Astin used to treat conditions other than its primary indication?

Official approvals for Astin extend beyond its primary purpose to include therapeutic use for both the primary and secondary prevention of cardiovascular events. This secondary prevention involves reducing the risk of heart attacks and strokes in high-risk patients.


Q: Does Astin require regular blood tests or monitoring?

Official product information states that monitoring is required. Regulatory labeling indicates that liver function tests are necessary prior to the initiation of treatment and periodically thereafter. Lipid levels are typically analyzed after two to four weeks following initiation or dosage change to assess therapeutic effect.


Q: Does Astin have any known interactions with herbal supplements?

Yes, regulatory documents note a specific interaction with the herbal supplement St. John’s Wort. Taking St. John’s Wort can cause Astin levels in the blood to decrease, potentially reducing the medicine's effectiveness. Safety protocols require that all herbal and dietary supplements used concurrently be reviewed with a healthcare professional.


Q: How does Astin differ from older medicines for the same condition?

Astin belongs to the Statin class, but it is classified as a long-acting medicine. Its active effect on the body's cholesterol production lasts for approximately 20 to 30 hours, which is longer than some older medicines in the same class. This characteristic contributes to the drug's established administrative frequency.


Q: Is Astin available as a generic medicine?

Yes, the active ingredient in Astin, Atorvastatin calcium, is widely available as a generic prescription medicine. The availability of the generic version is based on regulatory and manufacturing guidelines.


Q: Does Astin interact with common over-the-counter pain relievers?

Official drug interaction lists do not typically specify common over-the-counter (OTC) pain relievers as having major interactions with Astin. However, the official patient information emphasizes the importance of professional review for all co-administered drugs.


Q: How long does Astin stay in the body after the last dose?

The mean elimination half-life of the parent drug is approximately 14 hours. However, the medicine has active metabolites that continue to work, extending the half-life of its cholesterol-reducing action to 20 to 30 hours. This sustained activity is a key factor in the medicine’s dosage schedule.


Q: Is Astin safe for people with pre-existing heart conditions?

Official indications show that Astin is used in people with established coronary artery disease, which is a pre-existing heart condition. In this context, the medicine is used for secondary prevention—to help reduce the risk of future events like heart attacks and strokes. Patient eligibility for this use is evaluated by a healthcare professional.


Q: Do studies support the long-term use of Astin?

Studies confirm that the therapeutic benefit of Astin is maintained during chronic use. However, the official regulatory label also notes that for some outcomes, long-term effects beyond the duration of the original clinical trials are still being characterized.


Q: What is the general success rate mentioned in research for Astin?

Research measures the drug's effectiveness by tracking the reduction of blood lipid markers, particularly LDL cholesterol. Official clinical trial data shows a dose-dependent reduction, with higher doses typically achieving a greater percentage decrease in LDL-C levels.


Q: Why is Astin sometimes used together with other therapies?

Astin may be used alongside other lipid-modifying agents to achieve an additive effect on a patient’s cholesterol profile. The goal of this combination therapy is to improve lipid levels beyond what is achieved with Astin alone. Any such combination requires careful management due to potential interaction risks.


Q: Does Astin have different effects on men versus women?

Official clinical studies indicate that Astin has been found to be effective across a wide variety of patient populations. The documented therapeutic effects were observed across both male and female populations, supporting its general adult indication.


Q: Can Astin be crushed, split, or chewed?

Astin is supplied as a film-coated tablet, which typically means it should be swallowed whole to ensure the correct release of the medication. For patients who have difficulty swallowing, the manufacturer has also made a chewable tablet formulation available.


Q: Is Astin mentioned in any major medical treatment guidelines?

As a member of the Statin class, Astin is an established medicine in clinical practice. The Statin class itself is widely referenced in professional medical guidelines for managing abnormal lipid levels and reducing cardiovascular risk.


Q: Can Astin be used by people who are lactose intolerant?

Official product information states that the tablets contain lactose monohydrate, an inactive ingredient. The medicine is contraindicated for patients with a known hypersensitivity to any of its components, including excipients like lactose.


Q: Are there specific symptoms that indicate Astin is working?

Astin works by lowering blood lipid levels such as LDL cholesterol, which does not produce immediate or noticeable physical symptoms. Effectiveness is assessed by laboratory blood tests conducted under the direction of a healthcare professional.


Q: Does Astin affect fertility?

Official safety information includes a strict contraindication for use during pregnancy, based on the potential for fetal harm. For this reason, official guidance indicates that effective contraception is advised for females of reproductive potential during treatment.


Q: What is the half-life of Astin?

The mean elimination half-life of the parent drug, the time it takes for half of it to leave the body, is approximately 14 hours. However, the drug's active metabolites contribute to a longer half-life of inhibitory activity, extending the cholesterol-reducing effect to 20 to 30 hours. This sustained activity is a key factor in the medicine’s dosage schedule.


Q: Does Astin come with a Medication Guide or Patient Information leaflet?

Yes, regulatory requirements ensure that the product is supplied with FDA-approved patient labeling. This documentation provides essential information to patients, often in the form of a Patient Counseling Information sheet or a Medication Guide.

How should Astin be stored and disposed of?

How to Store and Dispose of Astin (Atorvastatin)

The storage and disposal requirements for Astin film-coated tablets are defined by regulatory agencies to ensure product stability and environmental safety.

Storage Requirements

Astin must be stored at controlled room temperature, maintaining a temperature below 30 C. It is mandatory to keep the medicine in a closed container and store it away from moisture, direct light, and excessive heat. The tablets must be explicitly kept from freezing.

For safety, the product must be stored out of the reach of children.

Disposal Instructions

Expired or unused Astin must be disposed of in accordance with local requirements. Due to environmental restrictions, the product must not be dumped into sewers or waterways, as releases of the active ingredient to the environment should be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Astin found in:

A-Z Index: